The diagnosis, management, and role of hematopoietic stem cell transplantation in aggressive peripheral T-cell neoplasms

Cancer Control

Volumn 14, Issue 2, 2007, Pages 151-159

  Rezania, Dorna ^a   Cualing, Hernani D ^a   Ayala, Ernesto ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DENILEUKIN DIFTITOX; DOXORUBICIN; ENZYME INHIBITOR; HISTONE ACETYLTRANSFERASE INHIBITOR; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD7; PENTOSTATIN; PREDNISONE; PURINE DERIVATIVE; UNCLASSIFIED DRUG; VINCRISTINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELL INFILTRATION; CELL STRUCTURE; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOGENETICS; DIFFERENTIAL DIAGNOSIS; DRUG MEGADOSE; ENTEROPATHY ASSOCIATED T CELL LYMPHOMA; EPSTEIN BARR VIRUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC SYNDROME; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; IMMUNOPHENOTYPING; LOW DRUG DOSE; OPPORTUNISTIC INFECTION; PERIPHERAL T CELL LYMPHOMA; PROGNOSIS; REVIEW; SURVIVAL RATE; T CELL PROLYMPHOCYTIC LEUKEMIA;

EID: 34047191881     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480701400208     Document Type: Review

References (50)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89:3909-3918.
2. Coiffier B. Non-Hodgkin's lymphoma. Diagnosis, principles of treatment [in French]. Rev Prat. 1990;40:669-671.
3. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood. 1998;92:76-82.
4. Streubel B, Vinatzer U, Willheim M, et al. Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia. 2006;20:313-318.
5. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002-1006.
6. Kim JG, Sohn SK, Chae YS, et al. CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol. 2006;58:35-39. Epub 2005 Nov 25.
7. Tsimberidou AM, Giles F, Romaguera J, et al. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies. Cancer. 2004;100:574-580.
8. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103:2920-2924. Epub 2003 Dec 30.
9. Au WY, Ma SY, Chim CS, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol. 2005;16:206-214.
10. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16:2780-2795.
11. Martel P, Laroche L, Courville P, et al. Cutaneous involvement in patients with angioimmunoblastic lymphadenopathy with dysproteinemia: a clinical, immunohistological, and molecular analysis. Arch Dermatol. 2000;136:881-886.
12. Grogg KL, Attygale AD, Macon WR, et al. Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. Mod Pathol. 2006;19:1101-1107.
13. Yuan CM, Vergilio JA, Zhao XF, et al. CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry. Hum Pathol. 2005;36:784-791.
14. Schlegelberger B, Feller A, Godde E, et al. Stepwise development of chromosomal abnormalities in angioimmunoblastic lymphadenopathy. Cancer Genet Cytogenet. 1990;50:15-29.
15. Vrsalovic MM, Korac P, Dominis M, et al. T- and B-cell clonality and frequency of human herpes viruses-6, -8 and Epstein Barr virus in angioimmunoblastic T-cell lymphoma. Hematol Oncol. 2004;22:169-177.
16. Greer JP, Kinney MC, Loughran TP, Jr. T cell and NK cell lymphoproliferative disorders. Hematology Am Soc Hematol Educ Program. 2001;259-281.
17. Ghobrial IM, Weenig RH, Pittlekow MR, et al. Clinical outcome of patients with subcutaneous panniculitis-like T-cell lymphoma. Leuk Lymphoma. 2005;46:703-708.
18. Schetelig J, Fetscher S, Reichle A, et al. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica. 2003;88:1272-1278.
19. Jaffe E Harris, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
20. Matutes E, Brito-Babapulle V, Swansbury J, et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood. 1991;78:3269-3274.
21. Brito-Babapulle F, Huang D, Lavender P, et al. Regression of intracerebral lesions in T prolymphocytic leukaemia treated with intravenous deoxycoformycin. Eur J Haematol. 1988;40:185-187.
22. Pawson R, Dyer MJ, Barge R, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol. 1997;15:2667-2672.
23. Sallah S, Smith SV, Lony LC, et al. Gamma/delta T-cell hepatosplenic lymphoma: review of the literature, diagnosis by flow cytometry and concomitant autoimmune hemolytic anemia. Ann Hematol. 1997;74:139-142.
24. Cooke CB, Krenacs L, Stetler-Stevenson M, et al. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood. 1996;88:4265-4274.
25. Arnulf B, Copie-Bergman C, fau-Larue MH, et al. Nonhepatosplenic gammadelta T-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or skin localization. Blood. 1998;91:1723-1731.
26. Belhadj K, Reyes F, Farcet JP, et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood. 2003;102:4261-4269. Epub 2003 Aug 7.
27. Boulland ML, Kanavaros P, Wechsler J, et al. Cytotoxic protein expression in natural killer cell lymphomas and in alpha beta and gamma delta peripheral T-cell lymphomas. J Pathol. 1997;183:432-439.
28. Wlodarska I, Martin-Garcia N, Achten R, et al. Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression. Genes Chromosomes Cancer. 2002;33:243-251.
29. Narducci MG, Pescarmona E, Lazzeri C, et al. Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Res. 2000;60:2095-2100.
30. Van Overbeke L, Ectors N, Tack J. What is the role of celiac disease in enteropathy-type intestinal lymphoma? A retrospective study of nine cases. Acta Gastroenterol Belg. 2005;68:419-423.
31. Hayashi K, Nakamura S, Koshikawa T, et al. A case of CD56-positive peripheral T-cell lymphoma presenting with giant tumor of the gastrointestinal tract during the course [in Japanese]. Nippon Shokakibyo Gakkai Zasshi. 1994;91:317-321.
32. Reiser M, Josting A, Soltani M, et al. T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors. Leuk Lymphoma. 2002;43:805-811.
33. Morabito F, Gallamini A, Stelitano C, et al. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lympomas. Cancer. 2004;101:1601-1608.
34. Zinzani PL, Bendandi M, Martelli M, et al. Anaplastic large cell lymphoma: clinical and prognostic evaluation of 90 adult patients. J Clin Oncol. 1996;14:955-962.
35. Savage KG. Aggressive peripheral T-cell lymphomas (specified and unspecified types). Hematology. 2005;1:267-277.
36. Sonnen R, Schmidt WP, Müller-Hermelink HK, et al. The international prognostic index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Hematol. 2005;129:366-372.
37. Peipp M, Kupers H, Saul D, et al. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res. 2002;62:2848-2855.
38. Blystad AK, Enblad G, Kvaloy S, et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant. 2001;27:711-716.
39. Rodriguez J, Munsell M, Yazji S, et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol. 2001;19:3766-3770.
40. Kahl C, Leithauser M, Wolff D, et al. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation. Ann Hematol. 2002;81:646-650.
41. Angelopoulou MK, Nademanee A, Dagis A, et al. Comparison of outcome of high dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) in peripheral T cell lymphoma (PTCL) vs. diffuse large B cell lymphoma (B-DLCL). Blood. 2003:102;867. Absrtact.
42. Rodriguez J, Caballero MD, Gutierrez A, et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol. 2003;14:1768-1775.
43. Song KW, Mollee P, Keating A, et al. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol. 2003;120:978-985.
44. Jantunen E, Wilkins T, Juvonen E, et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant. 2004;33:405-410.
45. Corradini P, Dodero A, Zallio F, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells . J Clin Oncol. 2004;22:2172-2176.
46. Majhail NS, Burns LJ. Hematopoietic stem cell transplantation in the treatment of peripheral T-cell lymphomas. Curr Hematol Rep. 2005;4:252-259.
47. Deconinck E, Lamy T, Focussed C, et al. Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. Br J Haematol. 2000;109:736-742.
48. Reimer P, Schertein T, Rudiger T, et al. Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. Hematol J. 2004;5:304-311.
49. Jantunen E, Juvonen E, Wiklund T, et al. High-dose therapy supported by autologous stem cell transplantation in patients with enteropathy-associated T-cell lymphoma. Leuk Lymphoma. 2003;44:2163-2164.
50. Mansour MR, Dogan A, Morris EC, et al. Allogeneic transplantation for hepatosplenic alphabeta T-cell lymphoma. Bone Marrow Transplant. 2005;35:931-934.